Special notice
The Food and Drug Administration (FDA) intends to award a sole source contract to the Reagan-Udall Foundation for the FDA (RUF) to support execution of its ts congressionally mandated regulatory mission across 16 project areas
FDASSOC136354
Food and Drug Administration, FDA Negotiated Contracts Branch. Other Management Consulting Services.
Response deadline
September 21, 2026 at 1:30 PM EDT
Closed in 5 days. Posted September 14, 2026. Scheduled to archive October 6, 2026.
Description
As published on SAM.gov.
The Food and Drug Administration (FDA) intends to award a sole source contract to the Reagan-Udall Foundation for the FDA (RUF) to support execution of its congressionally mandated regulatory mission across 16 project areas addressing high-priority regulatory science gaps and public health challenges. The work — spanning structured stakeholder engagement, independent scientific convening, and landscape research — is a prerequisite to FDA's ability to develop sound regulatory frameworks and fulfill statutory obligations.
Each project area targets a specific gap where FDA cannot act without the scientific foundation, stakeholder input, or evidence infrastructure this contract provides. The contract is framed as a high-value investment: the cost of inaction — measured in delayed regulatory frameworks, preventable harm, and eroded public trust — exceeds the cost of the engagement.
See Attachment for Intent to Sole Source Posting
See Attachment for Draft Statement of Work
Attachments
Files listed on SAM.gov. The ones we hold a copy of download from here; the rest open SAM's download, which needs no account.
- Intent to Sole Source DRAFT 9 14 2026 1152 AM.pdf80 KB, September 14, 2026, mirrored
- STATEMENT OF WORK DRAFT 9 14 2026.pdf486 KB, September 14, 2026, mirrored
Publications
Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.
September 14, 2026
Special notice
Due September 21, 2026 at 1:30 PM EDT. SAM.gov, notice 43375f32d074401ebb2bb3897fc0cad9
1 revisions on SAM
- September 14, 2026: publish, special notice
Points of contact
- Howard Yablonhoward.yablon@fda.hhs.gov
- Ian Weissian.weiss@fda.hhs.gov